Chongqing Joywin

Joywin Biopharma, officially known as Chongqing Joywin Pharmaceutical Co., Ltd., is a Chinese biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. As the primary research and development subsidiary of Pharscin Pharmaceutical, the company focuses on high-unmet-need areas within oncology and gastroenterology. Its lead clinical program, WNT-001, is a novel Porcupine inhibitor targeting the Wnt signaling pathway for the treatment of advanced solid tumors. Joywin integrates modern drug discovery technologies with its parent company's established manufacturing and commercialization infrastructure to accelerate the delivery of new medicines to the market.